UBS Maintains Neutral on Nuvation Bio, Lowers Price Target to $7
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Michael Yee maintains Nuvation Bio (NYSE:NUVB) with a Neutral and lowers the price target from $10 to $7.
UBS analyst Michael Yee maintains Nuvation Bio (NYSE:NUVB) with a Neutral and lowers the price target from $10 to $7.